{"article_title": "Roche to Buy Santaris Pharma", "article_keywords": ["buy", "pharma", "ways", "zurichroche", "rnatargeting", "million", "roche", "switzerland", "santaris", "statement", "swiss", "specializes", "relatively"], "article_url": "http://www.wsj.com/articles/roche-to-buy-santaris-pharma-1407168358", "article_text": "ZURICH\u2014Roche Holding AG said Monday it was buying Danish biopharmaceutical firm Santaris Pharma for as much $450 million, as the Swiss giant looks for ways to develop drugs for diseases difficult to address with existing medicines.\n\nRoche, based in Basel, Switzerland, said in a statement that it would make an initial cash payment of $250 million for privately held Santaris, which specializes in relatively new RNA-targeting...", "article_metadata": {"article.template": "snippet", "article.created": "2014-08-04T16:05:00.000Z", "article.section": "Business", "page.region": "na,us", "page.content.type": "Article", "twitter": {"domain": "wsj.com", "description": "Roche will pay an initial $250 million and further payments of up to $200 million for the Danish biopharmaceutical company, which specializes in so-called RNA-targeting therapeutics", "creator": "@letzing", "image": {"alt": "Roche to buy Danish biopharmaceutical company Santaris Pharma for up to $450 million", "identifier": "http://si.wsj.net/img/WSJ_Logo_black_social.gif"}, "title": "Roche to Buy Santaris Pharma", "site": "@WSJ", "card": "summary"}, "al": {"ios": {"url": "wsj://launch?articleid=SB10001424052702303967904580071503119016496&headline=Roche%20to%20buy%20Danish%20biopharmaceutical%20company%20Santaris%20Pharma%20for%20up%20to%20%24450%20million&weburl=http://www.wsj.com/articles/SB10001424052702303967904580071503119016496"}}, "page.site.product": "WSJ", "keywords": "biopharmaceuticals,disease,pharma takeover,rna-targeting,Roche Holding,ROG.VX,Santaris Pharma,ownership changes,acquisitions,mergers,takeovers,corporate actions,corporate,industrial news,biotechnology,pharmaceuticals,medical equipment,supplies,health care,life sciences,drugs,medication,medical,surgical instruments,apparatus,devices,therapeutic devices,equipment", "news_keywords": "biopharmaceuticals,disease,pharma takeover,rna-targeting,Roche Holding,ROG.VX,Santaris Pharma,ownership changes,acquisitions,mergers", "article.headline": "Roche to buy Danish biopharmaceutical company Santaris Pharma for up to $450 million", "description": "Roche will pay an initial $250 million and further payments of up to $200 million for the Danish biopharmaceutical company, which specializes in so-called RNA-targeting therapeutics", "apple-itunes-app": "app-id=364387007,app-argument=wsj://launch?articleid=SB10001424052702303967904580071503119016496&headline=Roche%20to%20buy%20Danish%20biopharmaceutical%20company%20Santaris%20Pharma%20for%20up%20to%20%24450%20million&weburl=http://www.wsj.com/articles/SB10001424052702303967904580071503119016496", "user.type": "nonsubscriber", "article.page": "News", "page.content.format": "responsive", "article.summary": "Roche will pay an initial $250 million and further payments of up to $200 million for the Danish biopharmaceutical company, which specializes in so-called RNA-targeting therapeutics", "page.site": "wsj", "testkeys": "C", "article.published": "2014-08-04T17:09:00.000Z", "dj.asn": "i-8b06", "robots": "noarchive,noodp", "fb": {"app_id": 368513495882}, "article": {"internal_link_count": 3, "word_count": 248, "publisher": "https://www.facebook.com/wsj"}, "viewport": "width=device-width, initial-scale=1.0, minimum-scale=1.0, maximum-scale=1.0, user-scalable=no", "page.section": "Article", "language": "en-US", "og": {"site_name": "WSJ", "description": "Roche will pay an initial $250 million and further payments of up to $200 million for the Danish biopharmaceutical company, which specializes in so-called RNA-targeting therapeutics", "title": "Roche to Buy Santaris Pharma", "url": "http://www.wsj.com/articles/roche-to-buy-santaris-pharma-1407168358", "image": {"width": 1200, "identifier": "http://si.wsj.net/img/WSJ_Logo_black_social.gif", "height": 630}, "locale": "en_US", "type": "article"}, "author": "John Letzing", "article.access": "paid", "page.content.source": "WSJ Online Article", "article.origheadline": "Roche to Buy Santaris Pharma", "article.type": "European Business News", "article.id": "SB10001424052702303967904580071503119016496", "user.exp": "default", "article.updated": "2014-08-04T17:09:00.000Z"}, "_id": "\"57477af46914bd0286fe2a00\"", "article_summary": "Roche, based in Basel, Switzerland, said in a statement that it would make an initial cash payment of $250 million for privately held Santaris, which specializes in relatively new RNA-targeting...\nZURICH\u2014Roche Holding AG said Monday it was buying Danish biopharmaceutical firm Santaris Pharma for as much $450 million, as the Swiss giant looks for ways to develop drugs for diseases difficult to address with existing medicines."}